Vyant Bio, Inc.

Ladies and gentlemen, thank you for your patience. You are holding for today's ViantBio second quarter 2021 conference call and webcast. At this time, we are gathering additional participants and will begin momentarily. We appreciate your patience and ask that you please continue to hold. Thank you. Good afternoon and welcome to the ViantBio second quarter 2021 conference call and webcast. Today, August 16, 2021, the company filed its quarterly report for the quarter ended June 30, 2021 on Form 10-Q, issued a press release summarizing its results, and provided an overview of the activities in the second quarter. Today's discussion is being recorded and will be available for replay. A replay of today's webcast will be available on the ViantBio website following today's call. Alternatively, the link can be sent to you by contacting IR at ViantBio.com. All participants on this line will be in a listen-only mode during the presentation. The presentation will be followed by a question-and-answer session. At this time, I would now like to turn the conference over to Jay Roberts, Chief Executive Officer of ViantBio. Please go ahead, sir.

Thank you, Operator, and thank you all for joining the ViantBio Investor Conference call and webcast for the second quarter of 2021. We're pleased to be having completed our first full quarter as ViantBio. Now that the merger activities between the former Cancer Genetics and Stamonix are completed, we have directed our full focus on executing on our business plan. It's also a great pleasure to speak with you today and share our enthusiasm and to give you some insight into how we envision the near-term future of Buy and Bio. Additionally, we're going to present the financial results of the second quarter, end of June 30th, 2021. On the call with me today is Buy and Bio's Chief Financial Officer, Andy LaFrance. Following the Safe Harbor Statement, I will provide a strategic overview and update on recent corporate developments and the vision ahead. Then Andy will take us through a brief financial update and discuss key accounting matters for the second quarter. I will make some closing remarks and then we will open up the lines for questions. I'll now turn the call over to our CFO, Andy LaFrance.

Andy LaFrance Thank you, Jay, and welcome to all. We'd like to remind everyone that various comments about future expectations, plans, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. My bio cautions that these forward-looking statements are subject to risks and uncertainties that may cause or ask results to differ materially from those indicated, including risks described in the company's filings with the SEC. Any forward-looking statements made on this conference call speak only of today's date, Monday, August 16, 2021, and ViantBio does not intend to update any of these forward-looking statements to reflect the events or circumstances that would occur after today's date. This conference call is also being recorded for audio rebroadcast on ViantBio's website at www.viantbio.com. With that, I would like to turn the call back over to Jay Roberts. Jay?